Difference between revisions of "Team:Tuebingen/einweiterer"
| Line 10,254: | Line 10,254: | ||
.warningContent span { | .warningContent span { | ||
font-size: 1.5rem; | font-size: 1.5rem; | ||
| + | } | ||
| + | |||
| + | @media screen and (max-width: 500px) { | ||
| + | .warningContent span { | ||
| + | font-size: 1.5rem; | ||
| + | } | ||
} | } | ||
| Line 10,415: | Line 10,421: | ||
<div class="row pt-5 pb-3 "> | <div class="row pt-5 pb-3 "> | ||
<div class="warningContent col-12"> | <div class="warningContent col-12"> | ||
| − | <span class="align-middle" style="font-family: 'Righteous'">GLP.exe - a safe and effective treatment for Diabetes Mellitus Type II</span> | + | <span class="align-middle" style="font-family: 'Righteous';color:#2ecc71;font-size: 2.7rem !important;">GLP.exe - a safe and effective treatment for Diabetes Mellitus Type II</span> |
</div> | </div> | ||
</div> | </div> | ||
| Line 10,438: | Line 10,444: | ||
<div class="row pt-5 pb-3 "> | <div class="row pt-5 pb-3 "> | ||
<div class="warningContent col-12 slide-in"> | <div class="warningContent col-12 slide-in"> | ||
| − | <span class="align-middle" style="font-family: 'Righteous'">Yet...</span> | + | <span class="align-middle" style="font-family: 'Righteous';color:#2ecc71; font-size: 3rem !important;">Yet...</span> |
</div> | </div> | ||
</div> | </div> | ||
| Line 10,456: | Line 10,462: | ||
<div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | ||
| − | <h2 class="display-4 mobileTitle" style="font-family: 'Righteous'">Current Drugs</h2> | + | <h2 class="display-4 mobileTitle" style="font-family: 'Righteous';color:#2ecc71;">Current Drugs</h2> |
<p class="text-justify mobileText">are expensive, require fine tuning and daily shots. | <p class="text-justify mobileText">are expensive, require fine tuning and daily shots. | ||
Moreover, they have severe side-effects, causing patients to skip doses.</p> | Moreover, they have severe side-effects, causing patients to skip doses.</p> | ||
| Line 10,475: | Line 10,481: | ||
<div class="row pt-5 pb-3 "> | <div class="row pt-5 pb-3 "> | ||
<div class="warningContent col-12"> | <div class="warningContent col-12"> | ||
| − | <span class="align-middle" style="font-family: 'Righteous'">However...</span> | + | <span class="align-middle" style="font-family: 'Righteous';color:#2ecc71;font-size: 3rem !important;">However...</span> |
</div> | </div> | ||
</div> | </div> | ||
| Line 10,494: | Line 10,500: | ||
<div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | ||
| − | <h2 class="display-4 mobileTitle" style="font-family: 'Righteous'">There's a solution!</h2> | + | <h2 class="display-4 mobileTitle" style="font-family: 'Righteous';color:#2ecc71;">There's a solution!</h2> |
<p class="text-justify mobileText">Our therapeutic agent is a probiotic secreting incretin | <p class="text-justify mobileText">Our therapeutic agent is a probiotic secreting incretin | ||
mimetics placed in the patients intestine by oral administration of capsules. GLP-1 and Exendin-4, our | mimetics placed in the patients intestine by oral administration of capsules. GLP-1 and Exendin-4, our | ||
| Line 10,510: | Line 10,516: | ||
<div class="row pt-5 pb-3 "> | <div class="row pt-5 pb-3 "> | ||
<div class="warningContent col-12"> | <div class="warningContent col-12"> | ||
| − | <span class="align-middle" style="font-family: 'Righteous'">Safety</span> | + | <span class="align-middle" style="font-family: 'Righteous';color:#2ecc71;font-size: 3rem !important;">Safety</span> |
</div> | </div> | ||
</div> | </div> | ||
| Line 10,529: | Line 10,535: | ||
<div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | ||
| − | <h2 class="display-4 mobileTitle" style="font-family: 'Righteous'">is our highest priority!</h2> | + | <h2 class="display-4 mobileTitle" style="font-family: 'Righteous';color:#2ecc71;">is our highest priority!</h2> |
<p class="text-justify mobileText">Therefore, we developed a novel, Cas3 based kill-switch | <p class="text-justify mobileText">Therefore, we developed a novel, Cas3 based kill-switch | ||
mechanism. The flexible system uses three regulators inspired by the human intestines: temperature, | mechanism. The flexible system uses three regulators inspired by the human intestines: temperature, | ||
| Line 10,544: | Line 10,550: | ||
<div class="row pt-5 pb-3 "> | <div class="row pt-5 pb-3 "> | ||
<div class="warningContent col-12"> | <div class="warningContent col-12"> | ||
| − | <span class="align-middle" style="font-family: 'Righteous'">Additionally</span> | + | <span class="align-middle" style="font-family: 'Righteous';color:#2ecc71;font-size: 3rem !important;">Additionally</span> |
</div> | </div> | ||
</div> | </div> | ||
| Line 10,563: | Line 10,569: | ||
<div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | <div class="col-12 col-md-6 pt-3" style="padding-right: 6vw;"> | ||
| − | <h2 class="display-4 mobileTitle" style="overflow-x: visible; font-family: 'Righteous'">An in depth E.coli Nissle characterization</h2> | + | <h2 class="display-4 mobileTitle" style="overflow-x: visible; font-family: 'Righteous';color:#2ecc71;">An in depth E.coli Nissle characterization</h2> |
<p class="text-justify mobileText">Despite the fact that E. Coli Nissle is an already | <p class="text-justify mobileText">Despite the fact that E. Coli Nissle is an already | ||
approved probiotic, it's surprisingly badly characterized.</p> | approved probiotic, it's surprisingly badly characterized.</p> | ||
| Line 10,582: | Line 10,588: | ||
<div class="row pt-5 pb-3 "> | <div class="row pt-5 pb-3 "> | ||
<div class="warningContent col-12 slide-in"> | <div class="warningContent col-12 slide-in"> | ||
| − | <span class="align-middle" style="font-family: 'Righteous'">Bringing it all together</span> | + | <span class="align-middle" style="font-family: 'Righteous';color:#2ecc71;font-size: 3rem !important;">Bringing it all together</span> |
</div> | </div> | ||
</div> | </div> | ||
Revision as of 19:36, 15 October 2019
Several treatment options for Type II Diabetes Mellitus have been developed in recent years significantly improving the patients' insulin level.
Hence, the diagnosis of Type II Diabetes Mellitus is no longer a death sentence.
Current Drugs
are expensive, require fine tuning and daily shots. Moreover, they have severe side-effects, causing patients to skip doses.
“Many patients don’t want to use insulin. They don’t want
to do finger sticks and they’re afraid of hypoglycemia.”
“To fight the global diabetes pandemic, we would ideally have an accessible cost-effective
easily-compliant intervention that has high clinical efficacy and that is free of adverse side effects.”
Prof. Harold Lebovitz, State University of New York Health Science Center, Brooklyn, New York
There's a solution!
Our therapeutic agent is a probiotic secreting incretin mimetics placed in the patients intestine by oral administration of capsules. GLP-1 and Exendin-4, our main actors, cause an increase in insulin secretion, if the cell has already taken up sugar.
This enables an easier therapy where a regular intake of medicals are not required.
Improved cell penetrating peptides with the use of artificial intelligence allow for an efficient and safe transport of our effectors into the cells.
is our highest priority!
Therefore, we developed a novel, Cas3 based kill-switch mechanism. The flexible system uses three regulators inspired by the human intestines: temperature, availability of fatty acids in form of Acyl CoA and N-Acetyl-Glucosamin.
If the conditions of our regulatory system are no longer met, Cas3 will be degrading all genetic information.
An in depth E.coli Nissle characterization
Despite the fact that E. Coli Nissle is an already approved probiotic, it's surprisingly badly characterized.
Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with common competitors for various fluxes in the gut.
Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E. coli Nissle to aerobic, as well as anaerobic occurring stress factors.
Our work lays the foundation for an innovative, unprecedented approach to treat Diabetes Mellitus Type II.
